<DOC>
	<DOCNO>NCT01318902</DOCNO>
	<brief_summary>This study include patient previously treat systemic relapsed refractory light-chain ( AL ) amyloidosis require therapy aim determine safety profile maximum tolerate dose/recommended phase 2 dose IXAZOMIB administer orally .</brief_summary>
	<brief_title>Study Oral IXAZOMIB Adult Patients With Relapsed Refractory Light Chain Amyloidosis</brief_title>
	<detailed_description />
	<mesh_term>Amyloidosis</mesh_term>
	<mesh_term>Ixazomib</mesh_term>
	<mesh_term>Glycine</mesh_term>
	<criteria>Male female patient 18 year old Biopsyproven systemic relapsed refractory lightchain ( AL ) amyloidosis , least 1 prior therapy , investigator 's opinion , require treatment If receive stem cell transplant , must least 3 month posttransplantation recover side effect Must measurable disease define serum differential free light chain concentration ≥ 40mg/L Must objective measurable organ ( heart kidney ) amyloid involvement Must cardiac biomarker risk stage I II disease Must adequate hematologic , hepatic , renal function Eastern Cooperative Oncology Group ( ECOG ) performance status 0 2 Female patient post menopausal , surgically sterile , agree practice 2 effective method contraception agree abstain heterosexual intercourse Male patient agree practice effective barrier contraception agree abstain heterosexual intercourse Voluntary write consent Exclusion Criteria Peripheral neuropathy great equal Grade 2 Cardiac status describe protocol Severe diarrhea ( ≥ Grade 3 ) controllable medication require administration total parenteral nutrition Known gastrointestinal condition procedure could interfere swallow oral absorption tolerance MLN9708 Uncontrolled infection require systematic antibiotic Known human immunodeficiency virus ( HIV ) positive , hepatitis B surface antigenpositive status , know suspect active hepatitis C infection Presence active malignancy exception nonmelanoma skin cancer , cervical cancer , treat earlystage prostate cancer provide prostatespecific antigen within normal limit , completely resect carcinoma situ Female patient lactate pregnant Major surgery within 14 day first dose study drug Serious medical psychiatric illness could , investigator 's opinion , potentially interfere completion treatment accord protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>